- Hemogenyx Pharmaceuticals said Friday its subsidiary Immugenyx had entered into a collaboration agreement with Orgenesis to develop the company's advanced hematopoietic chimeras.

Immugenyx said it would collaborate with Orgenesis on the further development and commercialization of the company's advanced hematopoietic chimeras, a new type of humanised mouse with a functional human immune system for disease modelling and the development of drugs and cell therapies.

'As a company committed to the discovery and development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Orgenesis, a premier service provider in the regenerative medicine industry and a pioneer in cell reprogramming. The commercial collaboration, license agreement and investment is an additional confirmation of the uniqueness and value of Immugenyx' AHC platform.' said Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx.

At 9:47am: [LON:HEMO] Hemogenyx Pharmaceuticals Plc share price was +0.2p at 2.95p

Story provided by